505 Odyssey Way
Merritt Island, FL 32953
United States
(254)244-5739
https://www.vaxxinity.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 57
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Louis Garfield Reese IV | Co-Founder & Executive Chairman of the Board | 275.57k | N/D | 1982 |
Ms. Mei Mei Hu J.D. | Co-Founder, President, CEO & Director | 345.14k | N/D | 1983 |
Ms. Sumita Ray J.D. | Chief Legal, Compliance & Administrative Officer and Corporate Secretary | 465.56k | N/D | 1974 |
Mr. Jason Pesile CPA, M.B.A. | Chief Accounting Officer | N/D | N/D | 1973 |
Dr. Jean-Cosme Dodart Ph.D. | Chief Scientific Officer | N/D | N/D | N/D |
Mr. Jon Harrison | Chief Government Officer | N/D | N/D | N/D |
Mr. Mark Joinnides MSE | Chief of Staff | N/D | N/D | N/D |
Ms. Amy B. Fix M.B.A., M.S., R.A.C. | Head of Regulatory | N/D | N/D | N/D |
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
La calificación ISS Governance QuickScore de Vaxxinity, Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 9; Junta: 9; Derechos del accionista: 10; Compensación: 7.